Ind-Swift Ltd.
Snapshot View

5.18 ▼0%

19 July 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.indswift.com
Financial Indicators
Market Cap 28.06 Cr.
Earnings per share (EPS) -5.50 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share -137.16 Trailing Twelve Months Ending 2021-03
Price to Book Value -0.04 Calculated using Price: 5.18
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 5.42 Cr. 54,164,653 Shares
FaceValue 2
Company Profile

Ind-Swift Limited was incorporated as a public limited company on June 6, 1986 under the Companies Act 1956.It is the flagship company of India based Ind Swift Group. Ind-Swift Limited is a north India based pharmaceutical company.

Ind Swift Group is a legendary forename in the world Class Pharmaceutical Industry who has broaden its horizons by plucking profound & sparkling footprints on multifarious diversified fronts, whilst going steadily and surely, scripting a success story filled with enviable milestones and pioneering breakthroughs and has subsequently emergent as a group with an annual turn over of 1000 Crore.

Manufacturing of Pharmaceutical finished dosage are carried out at 7 state-of-the art manufacturing facilities which are second to the none are duly certified and approved by WHO GMP, spread over an area of 12, 00, 000 sq. ft. with manufacturing capacities confirming to stringent TGA/MHRA approvals; possessing an installed capacities of 3 billion units comprising tablets, capsules, ointments, injectables, liquids & dry syrup (all latest formulations with a marketing network.

Business areas of the company are:

Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include the following:Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence

The company is also in health Publications- With the maiden issue in September, 2002; Ind-Swift’s Health Publication TRENDZ brings the latest in medical field to the medical fraternity. Routinely published four times a year, each issue of TRENDZ is devoted to important contemporary healthcare issues and medical issues of a particular specialty.

Ind Swift is known for it's reverse engineering ability with highly focused R & D capabilities (duly approved by Department of Science & Technology, Govt. of India) and is equipped with state-of-the-art equipment, facilities and talented pool of scientists and researchers.

  • A well accepted expertise in NDDS, in India and the world over.
  • A US patent for Clarie OD, with a market size of $300 million.
  • Another patent for Fexofenadine ODT with a market size of $2.5 billion.
  • Development of 10 new molecules with a market size of $6 billion.

Ind Swift’s efforts and achievements in taste masking of macrolides was India's first and remains the only feat of its kind in the country. The R &D department is also involved in creating international opportunities and alliances for CRAMS business, contributing significantly to the company's profitability. It also offers complete support to international partners for preparing and filing dossiers for finished dosages. By taking giant strides on roads less traveled, Ind-Swift has become one of India's fastest growing pharmaceutical companies.

Ind Swift has radianced up in infrastructures business in the name and style of “Ind Swift Infrastructures and developers Ltd, and has come up with a multi crore project named “Regalia Towers”, of course a society with 2 bedroom /3 bedroom flats and penthouses owing a mystique which is exemplary in itself which not only reflects a diversified transformative spell to infrastructures front but a unique state of art with the best of specifications also. In infrastructures, Ind Swift plans to be emergent with motels & Resorts project in the upcoming phases.

Awards/ Achievements

  • Ranked as one of the most promising pharmaceutical group in India by Express Pharma Pulse.
  • All India achievers award as legend in Business house category.
  • An ISO 9001, 2000 company.
  • Achieved Pharma Pulse award as fastest growing & most promising pharmaceutical company for three successive years.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
+4.86%
1 Month
+9.98%
3 Month
+31.14%
6 Month
+12.85%
1 Year
+82.39%
2 Year
+26.34%
5 Year
+3.19%
9 years 2012-06 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -7.76 -55.75 -112.51
Return on Capital Employed (%) 9.75 -3.10 -4.27 -10.41 -20.35 -56.22 -10.31 3.37 5.82
Return on Assets (%) -1.50 -7.48 -8.26 -11.09 -17.47 -42.12 -8.45 1.35 -3.19

Balance Sheet View Details

Particulars 9 years 2012-06 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 321 217 108 -40 -239 -611 -679 -677 -713
Non Curr. Liab. 301 609 596 549 679 672 694 659 661
Curr. Liab. 946 581 686 718 621 608 598 616 654
Minority Int.
Equity & Liab. 1,568 1,407 1,390 1,228 1,061 669 613 598 602
Non Curr. Assets 527 519 506 469 439 463 427 405 373
Curr. Assets 986 843 851 738 612 206 186 194 229
Misc. Exp. not W/O 55 45 33 21 10
Total Assets 1,568 1,407 1,390 1,228 1,061 669 613 598 602

Profit Loss View Details

Particulars 9 years 2012-06 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 1,590 393 570 417 304 263 270 289 330
Other Income 29 6 13 2 13 14 15 8 22
Total Income 1,620 399 583 419 317 277 284 297 352
Total Expenditure -1,499 -416 -604 -487 -461 -328 -264 -278 -306
PBIDT 120 -16 -21 -68 -144 -52 21 19 46
Interest -121 -86 -77 -40 -19 -16 -11 -4 -35
Depreciation -23 -18 -26 -39 -36 -36 -35 -34 -34
Taxation 3 10 9 2 0 -1 -1 -2
Exceptional Items -260 -28 27 6
PAT -21 -111 -116 -145 -200 -364 -54 8 -19

Cash Flow View Details

Particulars 9 years 2012-06 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 94 -146 103 86 -106 7 1 43 35
Cash Fr. Inv. -184 -28 -14 -6 -4 -4 -3 -14 -11
Cash Fr. Finan. 99 146 -89 -81 110 -11 -4 -13 -26
Net Change 9 -28 0 -1 0 -8 -5 16 -3
Cash & Cash Eqvt 46 18 18 17 17 9 4 20 17

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 55.55 55.55 55.55 55.55 55.55 55.55 55.55 55.55 55.55
Public 44.45 44.45 44.45 44.45 44.45 44.45 44.45 44.45 44.45
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 73.46 73.46 73.46 73.46 73.46 73.46 73.46 73.46 0.00

Announcements View Details

Tue, 13 Jul 2021
COMPLIANCE UNDER REGULATION 23(9) OF SEBI (LODR) REGULATIONS 2015 FOR RELATED PARTY TRANSACTIONS
COMPLIANCE UNDER REGULATION 23(9) OF SEBI (LODR) REGULATIONS 2015 FOR RELATED PARTY TRANSACTIONS
Thu, 08 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Amrender Kumar Yadav
Designation :- Company Secretary and Compliance Officer
Thu, 08 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018

Technical Scans View Details

Mon, 19 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%